EC Number   |
Activating Compound |
Reference |
|---|
    6.3.2.17 | 2-mercaptoethanol |
45 mM: 3.5fold enhancement of activity, 200 mM: 25% decrease in activity |
1057 |
| 6.3.2.17 | 2-mercaptoethanol |
inhbibition above 100 mM |
1062 |
| 6.3.2.17 | 2-mercaptoethanol |
maximal activity at 30-50 mM |
1069 |
| 6.3.2.17 | 2-mercaptoethanol |
maximal stimulation at 25 mM |
1062 |
| 6.3.2.17 | 3,3-difluoroglutamate |
i.e. beta,beta-difluoroglutamate??, , the effect on polyglutamylation is dependent on its position relative to the point of L-Glu ligation. When beta,beta-difluoroglutamate is the acceptor amino acid, i.e. point of attachment. Ligation of Glu is enhanced. When beta,beta-difluoroglutamate is one residue distal to the acceptor amino acid, further elongation is blocked |
1100 |
| 6.3.2.17 | 3,3-difluoroglutamate |
the incorporation of 3,3-difluoroglutamate promotes the further synthesis of polyglutamates |
1099 |
| 6.3.2.17 | dithiothreitol |
maximal stimulation at 2.5 mM |
1062 |
| 6.3.2.17 | pemetrexed |
treatment of 211-H cells results in significantly higher expression of foloylpolyglutamate synthase and reduced folate carrier 1. Pemetrexed shows potent cytotoxicity in 211-H cells |
691823 |
| 6.3.2.17 | Reducing agents |
absolutely dependent on |
1062, 1063, 1089, 1091 |
| 6.3.2.17 | Reducing agents |
beta-mercaptoethanol or DTT |
1062, 1063, 1091 |
